alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                                        <C>
<PERIOD-TYPE>                                    3-MOS 
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-31-1998
<CASH>                                         685,060
<SECURITIES>                                         0
<RECEIVABLES>                                  395,304
<ALLOWANCES>                                  (30,220)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      31,204,985
<DEPRECIATION>                              17,149,496
<TOTAL-ASSETS>                              22,143,264
<CURRENT-LIABILITIES>                          720,154
<BONDS>                                     14,996,352
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   6,426,758
<TOTAL-LIABILITY-AND-EQUITY>                22,143,264
<SALES>                                              0
<TOTAL-REVENUES>                             3,109,910
<CGS>                                                0
<TOTAL-COSTS>                                3,369,704
<OTHER-EXPENSES>                                49,733
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             144,279
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                 7,338,750
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 7,338,750
<EPS-PRIMARY>                                    86.23
<EPS-DILUTED>                                        0
        

</TABLE>
§ 211.56 Sanitation. ( a ) Any building used in the manufacture, processing, packing, or holding of a drug product shall be maintained in a clean and sanitary condition, Any such building shall be free of infestation by rodents, birds, insects, and other vermin (other than laboratory animals). Trash and organic waste matter shall be held and disposed of in a timely and sanitary manner.
( b ) There shall be written procedures assigning responsibility for sanitation and describing in sufficient detail the cleaning schedules, methods, equipment, and materials to be used in cleaning the buildings and facilities; such written procedures shall be followed.
( c ) There shall be written procedures for use of suitable rodenticides, insecticides, fungicides, fumigating agents, and cleaning and sanitizing agents. Such written procedures shall be designed to prevent the contamination of equipment, components, drug product containers, closures, packaging, labeling materials, or drug products and shall be followed. Rodenticides, insecticides, and fungicides shall not be used unless registered and used in accordance with the Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. 135).
( d ) Sanitation procedures shall apply to work performed by contractors or temporary employees as well as work performed by full-time employees during the ordinary course of operations.
Exhibit 32



EXHIBIT 32  SECTION 906 CERTIFICATIONS



Each of the undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Provena Foods Inc. (the Company), that, to his knowledge, the Quarterly Report of the Company on Form 10-Q for the period ended June 30, 2005,
fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of
operation of the Company.



Date: July 28, 2005



/S/ THEODORE L. ARENATheodore L. Arena, Chief Executive Officer/S/ THOMAS J. MULRONEYThomas J. Mulroney, Chief Financial Officer
<PAGE>   1
                                                                      EXHIBIT 11




Statement Regarding Computation of Earnings Per Share

(in 000's, except per share amounts)

<TABLE>
<CAPTION>
                                             Three Months Ended

                                            April 1,       April 3,
                                              2000           1999
<S>                                        <C>            <C>
Weighted average shares outstanding         47,247          48,437

Effect of dilutive securities                  107           1,083

Shares for diluted EPS                      47,354          49,520


Net income                                 $ 1,301        $ 21,155



Per share amounts:

  Basic                                    $  0.03        $   0.44


  Diluted                                  $  0.03        $   0.43


</TABLE>
#### § 20.116 Drug and device registration and listing information.

Information submitted to the Food and Drug Administration pursuant to section 510(a) through (j) of the Federal Food, Drug, and Cosmetic Act shall be subject only to the special disclosure provisions established in §§ 207.81 and 807.37 of this chapter.

[81 FR 60212, Aug. 31, 2016]
###### Editorial Note on Part 178

#### Editorial Note:

Nomenclature changes to part 178 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

#### § 178.3725 Pigment dispersants.

Subject to the provisions of this regulation, the substances listed in this section may be safely used as pigment dispersants in food-contact materials.

| Substances | Limitations |
| --- | --- |
| Dimethylolpropionic acid (CAS Reg. No. 4767-03-7) | For use only at levels not to exceed 0.45 percent by weight of the pigment. The pigmented articles may contact all foods under conditions of use A through H as described in Table 2 of § 176.170(c) of this chapter. |
| Phosphorylated tall oil fatty acids (CAS Reg. No. 68604-99-9), prepared by the reaction of dimethyl hydrogen phosphite with tall oil fatty acids | For use only at levels not to exceed 1.0 percent by weight of the pigment. The pigmented polymeric films may contact all food under conditions of use D, E, F, and G described in table 2 of § 176.170(c) of this chapter. |
| Propanoic acid, 3-hydroxy-2-(hydroxymethyl)-2-methyl-, compd. with 1,1′,1′′-nitrilotris [2-propanol] (1:1) (CAS Reg. No. 221281-21-6) | For use only at levels not to exceed 0.45 percent by weight of the pigment. The pigmented articles may contact all food under conditions of use A through H as described in Table 2 of § 176.170(c) of this chapter. |
| Siloxanes and silicones; cetylmethyl, dimethyl, methyl 11-methoxy-11-oxoundecyl (CAS Reg. No. 155419-59-3) | For use only at levels not to exceed 0.5 percent by weight of the pigment. The pigmented polymers may contact all foods under conditions of use C, D, E, F, and G described in Table 2 of § 176.170(c) of this chapter. |
| Trimethylolethane (CAS Reg. No. 77-85-0) | For use only at levels not to exceed 0.45 percent by weight of inorganic pigment. The pigmented articles may contact all food under conditions of use A through H described in Table 2 of § 176.170(c) of this chapter. |

[61 FR 43157, Aug. 21, 1996, as amended at 63 FR 35799, July 1, 1998; 64 FR 48292, Sept. 3, 1999; 64 FR 72273, Dec. 27, 1999; 65 FR 52909, Aug. 31, 2000]
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000891035
<NAME> CONCEPTS DIRECT, INC.
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1998
<CASH>                                       4,007,434
<SECURITIES>                                         0
<RECEIVABLES>                                  398,255
<ALLOWANCES>                                         0
<INVENTORY>                                 11,187,016
<CURRENT-ASSETS>                            26,873,786
<PP&E>                                      11,659,058
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              39,285,614
<CURRENT-LIABILITIES>                       15,803,171
<BONDS>                                      6,466,567
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       496,729
<OTHER-SE>                                  16,519,147
<TOTAL-LIABILITY-AND-EQUITY>                39,285,614
<SALES>                                     50,830,390
<TOTAL-REVENUES>                            50,830,390
<CGS>                                       28,672,895
<TOTAL-COSTS>                               53,584,529
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (2,772,195)
<INCOME-TAX>                                 (970,000)
<INCOME-CONTINUING>                        (1,802,195)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,802,195)
<EPS-PRIMARY>                                    (.36)
<EPS-DILUTED>                                    (.36)
        

</TABLE>
Editorial Note on Part 189
Editorial Note: Nomenclature changes to part 189 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 70 FR 40880, July 15, 2005; and 70 FR 67651, Nov. 8, 2005.

§ 189.130 Coumarin. ( a ) Coumarin is the chemical 1,2-benzopyrone, C9H6O2. It is found in tonka beans and extract of tonka beans, among other natural sources, and is also synthesized. It has been used as a flavoring compound.
( b ) Food containing any added coumarin as such or as a constituent of tonka beans or tonka extract is deemed to be adulterated under the act, based upon an order published in the Federal Register of March 5, 1954 (19 FR 1239).
( c ) The analytical methods used for detecting coumarin in food are in sections 19.016-19.024 of the “Official Methods of Analysis of the Association of Official Analytical Chemists,” 13th Ed. (1980), which is incorporated by reference. Copies may be obtained from the AOAC INTERNATIONAL, 481 North Frederick Ave., suite 500, Gaithersburg, MD 20877, or may be examined at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
[42 FR 14659, Mar. 15, 1977, as amended at 49 FR 10114, Mar. 19, 1984; 54 FR 24899, June 12, 1989]
Exhibit 32.2



CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of Wellman, Inc. (the "Company") on Form 10-Q for the period ended September 30, 2003 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Keith R. Phillips, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.







|By:/s/Keith R. PhillipsChief Financial Officer and
Vice President
|-----------------------------------------------------------------
##### 



EXHIBIT 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Front Range Capital Corporation (the
Company) on Form 10-QSB for the period ending June 30, 2003, as filed with
the Securities and Exchange Commission on the date hereof (the Report), I,
William A. Mitchell, Jr., Chief Executive Officer and President of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to § 906 of
the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.



| | /s/ William A. Mitchell, Jr.
William A. Mitchell, Jr.
Chief Executive Officer and President
| | -------------------------------------------------------------------------------------------

August 13, 2003

A signed original of this written statement required by Section 906 has been
provided to Front Range Capital Corporation and will be retained by Front Range
Capital Corporation and furnished to the Securities and Exchange Commission or
its staff upon request.
§ 182.8250 Choline bitartrate. ( a ) *Product.* Choline bitartrate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing practice.
**Exhibit 31 (a)**I, John Whetzell certify that:1. I have reviewed this quarterly report on Form 10-Q of Northland Cable Properties SevenLimited Partnership; 2. Based on my knowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, in lightof the circumstances under which such statements were made, not misleading with respect to theperiod covered by this quarterly report; 3. Based on my knowledge, the financial statements, and other financial information included inthis quarterly report, fairly present in all material respects the financial condition,results of operations and cash flows of the registrant as of, and for, the periods presentedin this quarterly report; 4. The registrant’s other certifying officer and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) for the registrant and we have: a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, to ensurethat material information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;  b) Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and  c) Disclosed in this report any change in the registrant’s internalcontrols over financial reporting that occurred during the registrant’s most recentfiscal quarter that has materially affected, or is reasonably likely to affect, theregistrant’s internal controls over financial reporting; and5. The registrant’s other certifying officer and I have disclosed, based on our most recentevaluation of internal controls over financial reporting, to the registrant’s auditors andboard of directors: a) All significant deficiencies and material weaknesses in the design oroperation of internal controls over financial reporting, which are reasonablylikely to adversely affect the registrant’s ability to record, process, summarizeand report financial information; and  b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal controls overfinancial reporting.**Date: 5-14-07**     /s/ JOHN S. WHETZELL John S. Whetzell
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7253 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7253

To amend section 3706 of title 10, United States Code, to eliminate the 
  submission of cost and pricing data after agreeing on the contract 
price as a defense to contract price adjustments for defective cost and 
                 pricing data, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 6, 2024

Mr. Deluzio (for himself and Mr. Moylan) introduced the following bill; 
         which was referred to the Committee on Armed Services

_______________________________________________________________________

                                 A BILL

 
To amend section 3706 of title 10, United States Code, to eliminate the 
  submission of cost and pricing data after agreeing on the contract 
price as a defense to contract price adjustments for defective cost and 
                 pricing data, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Best Price for Our Military Act of 
2024''.

SEC. 2. ELIMINATION OF LATE COST AND PRICING DATA SUBMISSION DEFENSE.

    Section 3706(c) of title 10, United States Code, is amended--
            (1) in paragraph (3) by striking ``or'' at the end;
            (2) in paragraph (4) by striking the period and inserting 
        ``; or''; and
            (3) by adding at the end the following:
            ``(5) the cost or pricing data were submitted by the prime 
        contractor or subcontractor after the date of agreement on the 
        price of the contract (or price of the modification) or, if 
        applicable consistent with subsection (a)(2), such other date 
        agreed upon between the parties.''.
                                 <all>
```
Abatement Order filed March 31, 2020.

In The

Fourteenth Court of Appeals

____________

NO. 14-19-00469-CV

____________

AZHAR M. CHAUDHARY, Appellant

V.

WENSHAN ZHANG, Appellee

On Appeal from County Court at Law No. 5

Fort Bend County, Texas

Trial Court Cause No. 19-CCV-064611

ABATEMENT ORDER

This appeal is from a judgment signed May 31, 2019. Appellant filed a 

notice of appeal on June 12, 2019. Appellant filed a Statement of Inability to 

Afford Payment of Court Costs in the trial court. “A party who files a Statement of 

Inability to Afford Payment of Court Costs cannot be required to pay costs except 

by order of the court as provided by this rule.” See Tex. R. Civ. P. 145(a). The 

clerks’ record filed January 2, 2020, did not contain a contest to appellant’s 

statement and did not reflect that appellant has been ordered to pay costs pursuant 

to Rule 145.
Accordingly, on February 4, 2020, the official court reporter for the 234th 

District Court was directed to file the reporter’s record by March 5, 2020. See Tex. 

R. App. P. 35.1. On March 3, 2020, the court reporter filed an information sheet 

which states a contest of inability to afford payment of court costs was set for a 

hearing on October 17, 2019, but appellant moved for a continuance. On March 5, 

2020, appellant filed a motion for extension of time to file the reporter’s record. 

Appellant’s motion states the court reporter filed a contest on October 8, 2019, 

“which is pending in the trial court.”

Accordingly, we abate this appeal and direct the judge of County Court at 

Law No. 5 to conduct a hearing on the contest filed by the court reporter to 

appellant’s statement of inability to afford payment of court costs. See Tex. R. Civ. 

P. 145(f). We order the court to prepare a record, in the form of a reporter’s record, 

of the hearing. The judge shall order the trial clerk to forward to this court a 

supplemental clerk’s record containing the trial court’s findings, any rulings, 

and/or any orders on the contest. See id. The hearing record and supplemental 

clerk’s record shall be filed with the clerk of this court within 45 days of the date 

of this order.

The appeal is abated, treated as a closed case, and removed from this court’s 

active docket. The appeal will be reinstated on this court’s active docket when the 

hearing record and supplemental clerk’s records are filed in this court. The court 

will also consider an appropriate motion to reinstate the appeal filed by either 

party, or the court may reinstate the appeal on its own motion. 

PER CURIAM

Panel consists of Chief Justice Frost and Justices Jewell and Spain.
#### § 343.3 Definitions.

As used in this part:

*Analgesic* —*antipyretic drug.* An agent used to alleviate pain and to reduce fever.

*Cardiovascular drug.* An agent used to prevent ischemic events.

*Rheumatologic drug.* An agent used for the treatment of rheumatologic disorders.
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 07-1568
JESSIE B. HAYES, Plaintiff - Appellant, v. JACK POTTER, Postmaster General US Postal Service; POSTMASTER, Mount Pleasant Post Office, Mount Pleasant, SC, Defendants - Appellees. Appeal from the United States District Court for the District of South Carolina, at Charleston. David C. Norton, District Judge. (2:07-cv-00825-DCN) Submitted: February 28, 2008 Decided: March 3, 2008 Before WILKINSON, NIEMEYER, and MICHAEL, Circuit Judges. Affirmed by unpublished per curiam opinion. Jessie B. Hayes, Appellant Pro Se. Unpublished opinions are not binding precedent in this circuit.- 2 - PER CURIAM: Jessie B. Hayes appeals the district court’s order adopting the magistrate judge’s report and recommendation and dismissing her complaint alleging employment discrimination. We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. Hayes v. Potter , No. 2:07-cv-00825-DCN (D.S.C. June 1, 2007). We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED